argenx to buy Forte Biosciences for USD 77 per share in cash, valuing deal at USD 2.2 billion

Reuters2026/07/27 05:07

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

argenx agreed to buy Forte Biosciences in an all-cash deal priced at USD 77 per share, valuing equity at about USD 2.2 billion.
Price implies an 86% premium to Forte’s VWAP since reporting positive Phase 1b vitiligo data on July 9, 2026.
Deal adds lead asset FB102, a first-in-class anti-CD122 antibody with Phase 1b readouts in vitiligo and celiac disease.
Transaction is expected to close in Q3 2026; funding to come from argenx cash on hand.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Forte Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260726818072) on July 27, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

argenx to buy Forte Biosciences for USD 77 per share in cash, valuing deal at USD 2.2 billion

You may also like

Crypto prices